DOR Earnings Release 2005
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of
Report (Date of Earliest Event Reported): March
30, 2006
Commission
File No. 1-14778
DOR
BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its charter)
|
DELAWARE
|
|
41-1505029
|
|
(State
or other jurisdiction of incorporation or organization)
|
|
(I.R.S.
Employer Identification Number)
|
| |
|
|
|
1691
Michigan Ave., Suite 435
Miami,
FL
|
|
33139
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
| |
(305)
534-3383
|
|
| |
(Issuer’s
telephone number, including area code)
|
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[
]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
[
]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item 2.02. Results
of Operations and Financial Condition.
On
March 30, 2006, DOR BioPharma, Inc. issued a press release announcing its
results of operations for the year ended 2005. A copy of the press release
is
attached as Exhibit 99 to this report. This information is not deemed to be
“filed” for the purposes of Section 18 of the Securities Exchange Act of
1934 and is not incorporated by reference into any Securities Act registration
statements.
Item
9.01. Financial Statements and Exhibits.
(c)
Exhibits.
Exhibit
No. Title
99.1 Press
release issued by DOR BioPharma, Inc. on March 30, 2006.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
DOR
BIOPHARMA, INC.
By:
/s/
Michael T.
Sember
Name:
Michael T. Sember
Title:
President and Chief Executive Officer
Date:
March 30, 2006